Tern Plc Mathew Scherba seconded to Konektio

Tern plc

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things (“IoT”) technology businesses, has announced that it has agreed with the board of InVMA Limited, trading as Konektio, of which Tern currently owns 36.8% of the equity, and Konektio’s other investors, that Mathew Scherba, a director of Tern, will join the Konektio executive team for an initial two month period, with an option, on the mutual agreement of both parties, to further extend the secondment, to assist with the development of the Konektio business.

Mathew Scherba, will remain a director of Tern, fulfilling his duties and responsibilities at Tern, but will devote the majority of his time to assisting Konektio as it executes its growth plans, in particular the completion of the productisation of the next release of AssetMinder®, its modular, industry 4.0, IoT (software as a service) SaaS platform.  The agreement for Mr Scherba’s services will see Tern receive payments from Konektio, equal to the basic salary he is paid by Tern for the time he commits to Konektio.

Commenting Al Sisto, CEO of Tern, said:

“Tern’s hands-on approach with its portfolio companies is key to creating further value so that Tern shareholders can ultimately benefit from this value.  We are therefore pleased, with the agreement and support of Konektio’s other investors, to be able to provide Konektio with the benefit of Mathew Scherba’s skills and experience to help drive the completion of the productisation of their next exciting release of AssetMinder® and further expand their routes to market.

“All of the team at Tern continue to focus, in a hands-on manner, on maximising the investment value for Tern shareholders from our portfolio companies and I look forward to making further announcements on their progress in due course.”

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern increases convertible loan note investment in Talking Medicines

Tern has received £270,000 of new unsecured convertible loan notes from Talking Medicines, increasing its total convertible loan note holding to approximately £0.79 million while retaining a 23.8% equity stake.

Tern Plc invests $280,000 in Device Authority convertible loan notes

Tern has invested $280,000 in new unsecured convertible loan notes issued by Device Authority, forming part of a wider funding round of up to $1.6 million from existing investors.

Surgical training technology moves closer to the centre of precision medicine

Fundamental XR is targeting a critical adoption gap in advanced healthcare by using immersive simulation to help surgical teams prepare for complex procedures with greater consistency and scale.

GLP-1 therapies move into a wider investor debate

GLP-1 therapies are moving beyond weight loss and diabetes, creating a wider investor discussion around behaviour, risk and market positioning.

Tern raises £222,000 through share placing

Tern has raised £222,000 before expenses through a placing of 37 million new ordinary shares at 0.60 pence per share, with admission to AIM expected on or around 22 May 2026.

FundamentalXR targets surgical readiness for advanced eye therapies

FundamentalXR is targeting surgical readiness for advanced eye therapies with immersive simulation designed to support real-world adoption.

Search